Altimmune (ALT) Projected to Post Earnings on Tuesday

Altimmune (NASDAQ:ALT) will likely be releasing its Q1 2026 results before the market opens on Tuesday, May 12th. Analysts expect Altimmune to post earnings of ($0.25) per share and revenue of $0.0010 million for the quarter. Interested persons may visit the the company’s upcoming Q1 2026 earning results page for the latest details on the call scheduled for Tuesday, May 12, 2026 at 8:30 AM ET.

Altimmune (NASDAQ:ALT) last issued its quarterly earnings data on Thursday, March 5th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.25) by ($0.02). The firm had revenue of $0.03 million for the quarter, compared to analysts’ expectations of $0.00 million. Altimmune had a negative return on equity of 49.35% and a negative net margin of 214,860.98%. On average, analysts expect Altimmune to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Altimmune Price Performance

Shares of ALT traded up $0.03 during mid-day trading on Tuesday, hitting $3.05. 2,072,482 shares of the stock were exchanged, compared to its average volume of 4,610,475. The company has a market cap of $396.17 million, a PE ratio of -3.00 and a beta of 0.18. Altimmune has a 52-week low of $2.56 and a 52-week high of $7.73. The firm has a 50-day moving average of $3.50 and a two-hundred day moving average of $4.16. The company has a debt-to-equity ratio of 0.15, a quick ratio of 18.55 and a current ratio of 18.55.

Insider Buying and Selling

In other Altimmune news, CEO Jerome Benedict Durso acquired 20,000 shares of the business’s stock in a transaction on Friday, March 6th. The shares were bought at an average price of $3.54 per share, with a total value of $70,800.00. Following the transaction, the chief executive officer directly owned 32,500 shares of the company’s stock, valued at $115,050. The trade was a 160.00% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at this link. 1.60% of the stock is owned by company insiders.

Hedge Funds Weigh In On Altimmune

Several hedge funds have recently bought and sold shares of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Altimmune by 4.8% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 48,901 shares of the company’s stock valued at $247,000 after acquiring an additional 2,241 shares during the last quarter. The Manufacturers Life Insurance Company grew its position in Altimmune by 10.9% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 27,945 shares of the company’s stock valued at $108,000 after acquiring an additional 2,748 shares during the last quarter. Deutsche Bank AG grew its position in Altimmune by 4.0% in the 4th quarter. Deutsche Bank AG now owns 79,940 shares of the company’s stock valued at $289,000 after acquiring an additional 3,047 shares during the last quarter. Arax Advisory Partners grew its position in Altimmune by 99.7% in the 4th quarter. Arax Advisory Partners now owns 8,165 shares of the company’s stock valued at $29,000 after acquiring an additional 4,076 shares during the last quarter. Finally, BNP Paribas Financial Markets grew its position in shares of Altimmune by 108.5% during the 2nd quarter. BNP Paribas Financial Markets now owns 10,095 shares of the company’s stock worth $39,000 after buying an additional 5,253 shares in the last quarter. Institutional investors own 78.05% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on ALT. Barclays began coverage on Altimmune in a report on Tuesday, January 27th. They set an “overweight” rating and a $20.00 price objective on the stock. Wall Street Zen cut Altimmune from a “hold” rating to a “sell” rating in a report on Saturday, March 7th. HC Wainwright upped their price objective on Altimmune from $12.00 to $25.00 and gave the stock a “buy” rating in a report on Monday, March 16th. B. Riley Financial decreased their price objective on Altimmune from $18.00 to $13.00 and set a “buy” rating on the stock in a report on Friday, March 6th. Finally, William Blair restated a “market perform” rating on shares of Altimmune in a report on Thursday, March 5th. Seven equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $18.00.

Altimmune Company Profile

Altimmune, Inc is a clinical-stage biopharmaceutical company headquartered in Gaithersburg, Maryland, dedicated to the development of vaccines and immunotherapeutics. The company leverages proprietary technology platforms to create intranasal vaccine candidates and novel therapies targeting liver diseases and metabolic disorders. Altimmune’s approach emphasizes the stimulation of both systemic and mucosal immune responses to address unmet medical needs in infectious and chronic conditions.

Among its lead programs, NasoVAX is an investigational intranasal influenza vaccine designed to provide broad, long-lasting protection through a single, non-invasive dose.